Research Papers:
Ex vivo generation of umbilical cord blood T regulatory cells expressing the homing markers CD62L and cutaneous lymphocyte antigen
Metrics: PDF 1297 views | HTML 2300 views | ?
Abstract
Joshua N. Kellner1, Eric Yvon3 and Simrit Parmar1,2
1Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
2Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
3Department of Medicine, Hematology and Oncology, George Washington University School of Medicine, Washington, D.C, USA
Correspondence to:
Joshua N. Kellner, email: [email protected]
Keywords: regulatory T cells; immunotherapy; cell therapy; ex vivo expansion; cord blood
Received: June 19, 2018 Accepted: August 20, 2018 Published: September 14, 2018
ABSTRACT
Regulatory T cells (Tregs) are an important component of the immune system involved in regulation of immune cell proliferation and inflammatory responses and preventing autoimmune diseases. The use of Tregs in cellular therapy has recently been explored in clinical trials specifically evaluating the role of ex vivo expanded Tregs in the prevention of graft-versus-host disease during stem cell transplantation. The possibility of Treg use in the clinic requires clinical grade expansion of Tregs for development of cell therapy protocols and proper homing of Tregs to the intended target. Here we demonstrate a novel medium composition to expand CB Tregs, specifically upregulation the homing and activation markers CD62L and cutaneous lymphocyte antigen (CLA). CLA expression was uniquely acquired during activation of Tregs with subsequent loss or lack of expression with media change. This finding highlights the importance of proper growth conditions unique to Tregs that can alter expression of proteins and establishes a baseline for expanding marker specific Tregs that home and target unique tissues.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26097